Detail akcie Prothena Corporation PLC, Ordinary, Consolidated Issue listed on NASDAQ Global Market online

Business Summary: Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004). The Company has generated monoclonal antibodies that selectively bind to amyloidogenic (diseased) forms of the Transthyretin (TTR)-mediated amyloidosis (ATTR) protein. The Company's pipeline also includes late discovery-stage programs for which the Company is testing the efficacy of antibodies in preclinical models of diseases related to amyloid or cell adhesion.
Financial Summary: BRIEF: For the six months ended 30 June 2020, Prothena Corporation PLC revenues decreased 5% to $336K. Net loss increased 36% to $49.9M. Revenues reflect Collaboration revenue decrease of 19% to $286K. Higher net loss reflects Research and development - gross increase of 52% to $28.4M (expense), Interest income decrease of 71% to $1.3M (income), General and administrative - gross increase of 14% to $12.2M (expense).